$19.37
4.34% yesterday
Nasdaq, Aug 21, 10:00 pm CET
ISIN
US86366E1064
Symbol
GPCR

Structure Therapeutics Target price 2025 - Analyst rating & recommendation

Structure Therapeutics Classifications & Recommendation:

Buy
95%
Hold
5%

Structure Therapeutics Price Target

Target Price $76.50
Price $19.37
Potential
Number of Estimates 15
15 Analysts have issued a price target Structure Therapeutics 2026 . The average Structure Therapeutics target price is $76.50. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 19 analysts: 18 Analysts recommend Structure Therapeutics to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Structure Therapeutics stock has an average upside potential 2026 of . Most analysts recommend the Structure Therapeutics stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share $ -0.78 -1.07
3.70% 37.18%
P/E negative

14 Analysts have issued a Structure Therapeutics forecast for earnings per share. The average Structure Therapeutics EPS is

$-1.07
Unlock
. This is
2.88% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.86 17.31%
Unlock
, the lowest is
$-1.54 48.08%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.78 3.70%
2025
$-1.07 37.18%
Unlock
2026
$-1.51 41.12%
Unlock
2027
$-1.58 4.64%
Unlock
2028
$-1.80 13.92%
Unlock
2029
$-0.06 96.67%
Unlock
2030
$1.44 2,500.00%
Unlock
2031
$3.41 136.81%
Unlock
2032
$6.63 94.43%
Unlock

P/E ratio

Current -18.63 66.38%
2025
-18.04 3.14%
Unlock
2026
-12.80 29.05%
Unlock
2027
-12.23 4.45%
Unlock
2028
-10.77 11.94%
Unlock
2029
-316.50 2,838.72%
Unlock
2030
13.45 104.25%
Unlock
2031
5.67 57.84%
Unlock
2032
2.92 48.50%
Unlock

Current Structure Therapeutics Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Guggenheim
Locked
Locked
Locked Aug 07 2025
JMP Securities
Locked
Locked
Locked Aug 07 2025
HC Wainwright & Co.
Locked
Locked
Locked Aug 07 2025
Cantor Fitzgerald
Locked
Locked
Locked Jun 23 2025
JMP Securities
Locked
Locked
Locked Jun 23 2025
HC Wainwright & Co.
Locked
Locked
Locked May 12 2025
Citigroup
Locked
Locked
Locked May 02 2025
Analyst Rating Date
Locked
Guggenheim:
Locked
Locked
Aug 07 2025
Locked
JMP Securities:
Locked
Locked
Aug 07 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Aug 07 2025
Locked
Cantor Fitzgerald:
Locked
Locked
Jun 23 2025
Locked
JMP Securities:
Locked
Locked
Jun 23 2025
Locked
HC Wainwright & Co.:
Locked
Locked
May 12 2025
Locked
Citigroup:
Locked
Locked
May 02 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today